Data gathered: April 21
Alternative Data for Kala Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 8,837 | Sign up | Sign up | Sign up |
| Twitter Mentions | 6 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of therapies using its proprietary nanoparticle-based mucus penetrating particle (MPP) technology for the treatment of eye diseases. The company is headquartered in Watertown, Massachusetts.
| Price | $3.33 |
| Target Price | Sign up |
| Volume | 8,530 |
| Market Cap | $22M |
| Year Range | $3.27 - $11.02 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Kala Pharmaceuticals management to meet with OppenheimerApril 2 - Thefly.com |
 |
Tracking Baker Brothers Portfolio - Q4 2024 UpdateMarch 12 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 4.4M | -4.4M | -9M | 0 | 0.000 |
| Q2 '24 | 0 | 4.3M | -4.3M | -9.6M | -9.6M | -3.160 |
| Q1 '24 | 0 | 5.4M | -6.9M | -12M | -12M | -4.190 |
| Q4 '23 | 70,000 | 4.6M | -6.1M | -8.6M | -9.3M | -3.180 |
| Q3 '23 | 0 | 5M | -6.4M | -8.7M | -8.8M | -3.410 |
Insider Transactions View All
| Reumuth Mary filed to sell 68,581 shares at $7.6. January 7 '25 |
| Iwicki Mark T filed to sell 280,076 shares at $7.6. January 7 '25 |
| Brazzell Romulus K filed to sell 92,418 shares at $7.6. January 7 '25 |
| Kharabi Darius filed to sell 67,807 shares at $7.6. January 7 '25 |
Similar companies
Read more about Kala Pharmaceuticals (KALA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Kala Pharmaceuticals?
The Market Cap of Kala Pharmaceuticals is $22M.
What is the current stock price of Kala Pharmaceuticals?
Currently, the price of one share of Kala Pharmaceuticals stock is $3.33.
How can I analyze the KALA stock price chart for investment decisions?
The KALA stock price chart above provides a comprehensive visual representation of Kala Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Kala Pharmaceuticals shares. Our platform offers an up-to-date KALA stock price chart, along with technical data analysis and alternative data insights.
Does KALA offer dividends to its shareholders?
As of our latest update, Kala Pharmaceuticals (KALA) does not offer dividends to its shareholders. Investors interested in Kala Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Kala Pharmaceuticals?
Some of the similar stocks of Kala Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.